Prognostic subgroup | All patients | Cobimetinib + vemurafenib | Vemurafenib monotherapy | Dacarbazine | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
N (events) | ppOS, median, mo (95% CI) | 3-year ppOS, % (95% CI) | N (events) | ppOS, median, mo (95% CI), | 3-year ppOS, % (95% CI) | N (events) | ppOS, median, mo (95% CI) | 3-year ppOS, % (95% CI) | N (events) | ppOS, median, mo (95% CI) | 3-year ppOS, % (95% CI) | |
Normal LDH + stage IIIC/M1a/M1b | 240 (170) | 11.2 (9.7–14.0) | 23.1 (17.3–28.9) | 41 (28) | 10.5 (5.8–18.2) | 23.1 (8.8–37.5) | 129 (88) | 10.6 (7.1–14.9) | 23.8 (15.5–32.1) | 70 (54) | 13.3 (10.2–17.5) | 22.8 (12.6–32.9) |
Normal LDH + stage M1c + ppRx IT/TT | 98 (74) | 12.2 (10.3–16.1) | 23.4 (14.5–32.3) | 21 (14) | 14.4 (6.9–33.1) | 21.7 (0.0–44.2) | 50 (39) | 12.4 (10.3–18.4) | 22.3 (10.3–34.3) | 27 (21) | 11.8 (8.5–18.4) | 24.4 (7.8–41.1) |
Normal LDH + stage M1c + ppRx other + ECOG PS at PD 0 | 87 (72) | 8.2 (6.0–10.6) | 6.8 (0.7–13.0) | 19 (13) | 8.5 (3.2–21.4) | 8.6 (0.0–24.4) | 53 (45) | 7.7 (5.5–13.2) | 6.0 (0.0–13.6) | 15 (14) | 8.1 (5.8–14.1) | 6.7 (0.0–19.3) |
Normal LDH + stage M1c + ppRx other + ECOG PS at PD > 0 | 77 (71) | 3.6 (2.6–4.6) | 4.5 (0.0–9.4) | 11 (10) | 3.2 (1.3–5.4) | 0.0 (0.0–0.0) | 45 (41) | 4.1 (3.2–6.2) | 5.7 (0.0–13.0) | 21 (20) | 3.0 (1.6–8.3) | 4.8 (0.0–13.9) |
Elevated LDH (≤ 2 × ULN) + ppRx IT/TT | 79 (67) | 8.1 (6.7–12.9) | 11.4 (3.7–19.2) | 19 (17) | 9.2 (3.4–17.1) | 10.5 (0.0–24.3) | 42 (34) | 9.6 (7.0–17.2) | 14.1 (2.8–25.5) | 18 (16) | 6.6 (4.3–15.3) | 11.1 (0.0–25.6) |
Elevated LDH (≤ 2 × ULN) + ppRx other | 214 (186) | 4.2 (3.5–5.0) | 5.0 (1.1–8.8) | 44 (35) | 5.5 (4.1–11.9) | 8.4 (0.0–18.9) | 113 (95) | 4.1 (2.9–4.9) | 8.6 (2.8–14.3) | 57 (56) | 4.0 (3.0–5.4) | 0.0 (0.0–0.0) |
Elevated LDH (> 2 × ULN) | 160 (150) | 2.3 (1.8–2.7) | 2.7 (0.0–5.5) | 33 (29) | 2.4 (1.5–3.6) | NE (NE–NE) | 93 (89) | 2.4 (1.8–3.0) | 2.5 (0.0–5.8) | 34 (32) | 1.8 (1.2–3.3) | NE (NE–NE) |